Reduction in seroprevalence of viral transfusion‐transmitted infections in southwest Nigeria in children with sickle cell disease using an enhanced screening strategy

Abstract

Sickle cell disease (SCD) affects 3.2 million people globally and ~176 000 people die of SCD-related complications per year. 1 Nigeria alone has been estimated to have at least 150 000 newborns with SCD annually, a prevalence of 30 per 1000 live births has been reported in a regional newborn screening programme. 2 SCD is an autosomal recessive, genetic disorder in which red blood cells (RBCs) sickle in deoxygenated states due to single nucleotide polymorphism in which GTG is substituted for GAG (thymidine for adenine) at the sixth codon of the βglobin chain. This leads to chronic haemolysis, varying degrees of anaemia, and vaso-occlusive complications. 3,4 Despite a 10-fold rise in erythropoiesis, the haemolysis and resultant anaemia is only partially compensated, 3 can be exacerbated by factors related and unrelated to

HBV Genetic Diversity and Transfusion Safety: A Conceptual Analysis and Integrative Model

“…The analysis of the different tests in the transfusion medicine laboratory and their level of safety of labile blood products or blood components leads to two classes of resilience, namely maximum performance of the tests in the laboratory and a low risk blood product. Importantly,this integrative scheme can be used to identify gaps in the measurement of blood products and possibly develop new assessment tools to fill these gaps and overcome the difficulties associated with measuring donor blood components or blood bags [19,[49][50][51][52]. This is a prerequisite for a paradigm shift towards more patient-centred care, as this shift needs to be evaluated and monitored.…”